New Drug Futures (CNS)
Products that could change the pharma market to 2010 and beyond
| Price: £695.00 Approx $1,349.69 (USD) €1,038.06 (EUR) |
|
|---|---|
| Overview: | |
| This chapter of New Drug Futures evaluates, compares and contrasts the prospects for the compounds that will revolutionise the pharmaceutical industry over the next 5 years and beyond in the CNS sector. The report includes unique sales forecasts by major product. |
|
|
This paper is available from one of our partner sites.
Click here for details and to download it. |
|
By Dr CL Barton / Publication Date: 19th May 2006
Contents:
NEW DRUG FUTURES
CURRENT MARKET SIZE 1.
ADDRESSABLE PATIENT POPULATION 3
CURRENT TREATMENTS. 4
CNS SALES DRIVERS .5
CNS SALES BREAKERS 6
FUTURE TREATMENTS 7
MARKET DYNAMICS - WINNERS & LOSERS. 17
KEY DRUGS LAUNCHES BY 2010 . 18
KEY EVALUATION CRITERIA . 19
KEY CNS DRUG LAUNCHES BY 2010.20
Alzhemed (Neurochem). 20
Novelty/rationale for mechanism of action .20
Proof of concept/clinical data .20
Management/clinical expertise. 21
Competition within the marketplace/gaining share of voice .21
Risks associated with developing a drug within a therapeutic class .21
Filings and approval .21
Sales forecasts and assumptions .21
Competitor Ratio Analysis .22
Asenapine (Pfizer/Organon) . 22
Novelty/rationale for mechanism of action .22
Proof of concept/clinical data .22
Management/clinical expertise .22
Competition within the marketplace/gaining share of voice .23
Risks associated with developing a drug within a therapeutic class .23
Filings and approval .23
Sales forecasts and assumptions .23
Competitor Ratio Analysis .24
Bifeprunox (Wyeth/Solvay/Lundbeck) .24
Novelty/rationale for mechanism of action .24
Proof of concept/clinical data .24
Management/clinical expertise .25
Competition within the marketplace/gaining share of voice .25
Risks associated with developing a drug within a therapeutic class .25
Filings and approval .25
Sales forecasts and assumptions .25
Competitor Ratio Analysis .26
Champix (Pfizer) .26
Novelty/rationale for mechanism of action .26
Proof of concept/clinical data .26
Management/clinical expertise .26
Competition within the marketplace/gaining share of voice .27
Risks associated with developing a drug within a therapeutic class .27
Filings and approval .27
Sales forecasts and assumptions .27
Competitor Ratio Analysis .27
Daytrana (Shire) . 28
Novelty/rationale for mechanism of action .28
Proof of concept/clinical data 28
Management/clinical expertise .28
Competition within the marketplace/gaining share of voice .28
Risks associated with developing a drug within a therapeutic class .28
Filings and approval .29
Sales forecasts and assumptions .29
Competitor Ratio Analysis .29
DVS 233 ( Wyeth) .30
Novelty/rationale for mechanism of action .30
Proof of concept/clinical data .30
Management/clinical expertise .30
Competition within the marketplace/gaining share of voice .30
Risks associated with developing a drug within a therapeutic class .31
Filings and approval .31
Sales forecasts and assumptions .31
Competitor Ratio Analysis .31
Flurizan (Myriad Genetics) .32
Novelty/rationale for mechanism of action .32
Proof of concept/clinical data .32
Management/clinical expertise .32
Competition within the marketplace/gaining share of voice .33
Risks associated with developing a drug within a therapeutic class .33
Filings and approval .33
Sales forecasts and assumptions .33
Competitor Ratio Analysis .34
Gaboxodol (Lundbeck/Merck) .34
Novelty/rationale for mechanism of action .34
Proof of concept/clinical data .34
Management/clinical expertise .34
Competition within the marketplace/gaining share of voice .35
Risks associated with developing a drug within a therapeutic class .35
Filings and approval .35
Sales forecasts and assumptions .35
Competitor Ratio Analysis .36
Indiplon (Pfizer /Neurocrine) .36
Novelty/rationale for mechanism of action .36
Proof of concept/clinical data .36
Management/clinical expertise .36
Competition within the marketplace/gaining share of voice .37
Risks associated with developing a drug within a therapeutic class .37
Filings and approval .37
Sales forecasts and assumptions .37
Competitor Ratio Analysis .38
Laquinimod (Teva/Active Biotech) .38
Novelty/rationale for mechanism of action .38
Proof of concept/clinical data .38
Management/clinical expertise .39
Competition within the marketplace/gaining share of voice .39
Risks associated with developing a drug within a therapeutic class .39
Filings and approval .40
Sales forecasts and assumptions .40
Competitor Ratio Analysis .40
Lunesta/Estorra (Sepracor) .41
Novelty/rationale for mechanism of action .41
Proof of concept/clinical data .41
Management/clinical expertise .41
Competition within the marketplace/gaining share of voice .41
Risks associated with developing a drug within a therapeutic class .42
Filings and approval .42
Sales forecasts and assumptions .42
Competitor Ratio Analysis .42
Lurasidone (Dainippon Sumitomo Pharma/Merck & Co.) 42.
Novalty/rationale for mechanism of action .43
Proof of concept/clinical data .43
Management/clinical expertise .43
Competition within the marketplace/gaining share of voice .43
Risks associated with developing a drug within a therapeutic class .43
Filings and approval .44
Sales forecasts and assumptions .44
Competitor Ratio Analysis .44
Lyrica (Pfizer) . 44
Novelty/rationale for mechanism of action .44
Proof of concept/clinical data .45
Management/clinical expertise .45
Competition within the marketplace/gaining share of voice .46
Risks associated with developing a drug within a therapeutic class .46
Filings and approval .46
Sales forecasts and assumptions .47
Competitor Ratio Analysis .47
Mylinax (Serono/Ivax) . 48
Novelty/rationale for mechanism of action .48
Proof of concept/clinical data .48
Management/clinical expertise .48
Competition within the marketplace/gaining share of voice .48
Risks associated with developing a drug within a therapeutic class .49
Filings and approval .49
Sales forecasts and assumptions .49
Competitor Ratio Analysis .50
NS2359 (GlaxoSmithKline/NeuroSearch) .50
Novelty/rationale for mechanism of action .50
Proof of concept/clinical data .50
Management/clinical expertise .51
Competition within the marketplace/gaining share of voice .51
Risks associated with developing a drug within a therapeutic class. 52
Filings and approval .52
Sales forecasts and assumptions .52
Competitor Ratio Analysis .53
Paliperidone (Johnson & Johnson) .53
Novelty/rationale for mechanism of action .53
Proof of concept/clinical data .53
Management/clinical expertise .53
Competition within the marketplace/gaining share of voice .54
Risks associated with developing a drug within a therapeutic class .54
Filings and approval .54
Sales forecasts and assumptions .54
Competitor Ratio Analysis .55
Phenserine (Axonyx) .55
Novelty/rationale for mechanism of action .55
Proof of concept/clinical data .55
Management/clinical expertise .56
Competition within the marketplace/gaining share of voice .56
Risks associated with developing a drug within a therapeutic class .56
Filings and approval .56
Sales forecasts and assumptions .56
Competitor Ratio Analysis .57
Rozerem (Takeda) .57
Novelty/rationale for mechanism of action .57
Proof of concept/clinical data .57
Management/clinical expertise .58
Competition within the marketplace/gaining share of voice .58
Risks associated with developing a drug within a therapeutic class .58
Filings and approval .58
Sales forecasts and assumptions .58
Competitor Ratio Analysis .59
Saredutant (Sanofi-Aventis) . 59
Novelty/rationale for mechanism of action .59
Proof of concept/clinical data .59
Management/clinical expertise .60
Competition within the marketplace/gaining share of voice .60
Risks associated with developing a drug within a therapeutic class .60
Filings and approval .60
Sales forecasts and assumptions .60
Competitor Ratio Analysis .61
COMPETITOR RATIO ANALYSIS SUMMARY .62
COMPETITOR RATIO ANALYSIS – DRUGS .64
COMPETITOR RATIO ANALYSIS - COMPANIES .66
CONTENTS